Study Of Alvimopan Drug For Treatment Of Constipation Due To Prescription Pain Medication

This study has been completed.
Information provided by:
Cubist Pharmaceuticals Holdings LLC Identifier:
First received: January 18, 2005
Last updated: March 6, 2009
Last verified: March 2009

A multicenter study to evaluate the effectiveness and safety of multiple dosage regimens of an investigational drug for the treatment of constipation due to prescription pain medication in subjects with cancer pain. The study will require five visits over a five-week period.

Condition Intervention Phase
Bowel Dysfunction
Drug: alvimopan
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase IIb Study to Evaluate the Efficacy and Safety of Multiple Alvimopan Dosage Regimens for the Treatment of Opioid-Induced Bowel Dysfunction in Cancer Pain Subjects

Resource links provided by NLM:

Further study details as provided by Cubist Pharmaceuticals Holdings LLC:

Primary Outcome Measures:
  • Change in weekly SCBM frequency. A SCBM is a spontaneous and complete bowel movement, which means a bowel movement that occurs with no laxative use in the prior 24 hours and leaves the subject with the feeling of complete evacuation of the rectum.

Secondary Outcome Measures:
  • Additional measures of Bowel movement (BM) frequency and symptoms, safety profile of the treatment regimens and any changes in pain intensity or opioid use.

Estimated Enrollment: 215
Study Start Date: October 2003
Intervention Details:
    Drug: alvimopan
    Other Name: alvimopan

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion criteria:

  • Subject is in any stage of cancer but has a minimum life expectancy of at least 3 months at the time of the Screening Visit.
  • Subject is taking opioid therapy for persistent cancer pain.
  • Subject meets the definition of opioid-induced bowel dysfunction as follows: Since starting opioid therapy, the subject has had decreased BM frequency and at least one of the following constipation symptoms [sensation of incomplete evacuation, difficulty in expelling stool (straining), hard stools (abnormal stool consistency)].
  • Subject understands the procedures, agrees to participate in the study, and has signed and dated the informed consent form prior to the initiation of any study-related activities, including discontinuation of pre-study laxative regimen or other prohibited medications.
  • Subject is able and willing to comply with a daily paper diary and is capable of completing paper questionnaires at study visits.

Exclusion criteria:

  • Subject is pregnant or lactating, or planning to become pregnant.
  • Subject is not ambulatory.
  • Subject has participated in another trial with an investigational drug (unapproved), device or procedure within 30 days of the Screening Visit.
  • Subject is unable to eat, drink, take/hold down oral medications.
  • Subject is taking opioids for the management of drug addiction.
  • Subject is unable or unwilling to discontinue the use of and/or refrain from using laxatives of all types and formulation at the Screening Visit and throughout the entire study.
  • Subject has severe constipation that has not been appropriately managed such that the subject is at immediate risk of developing serious complications of constipation. This would include a subject who has reported no bowel movement for 7 consecutive days prior to the Screening Visit.
  • Subject with gastrointestinal or pelvic disorders known to affect bowel transit, produce gastrointestinal (GI) obstruction, or contribute to bowel dysfunction.
  • Subject is currently taking vinca alkyloids or plans to take vinca alkyloids during the study.
  • Subject is currently undergoing abdominal radiation therapy and/or plans to undergo abdominal radiation therapy during the study.
  • Subject is HIV-infected, has active hepatitis (any subtype including ongoing chronic hepatitis B), or has ever been infected with hepatitis C.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00101998

  Show 162 Study Locations
Sponsors and Collaborators
Cubist Pharmaceuticals Holdings LLC
Study Director: GSK Clinical Trials, MD GlaxoSmithKline
  More Information

No publications provided

Responsible Party: Study Director, GSK Identifier: NCT00101998     History of Changes
Obsolete Identifiers: NCT00903513
Other Study ID Numbers: 767905/008
Study First Received: January 18, 2005
Last Updated: March 6, 2009
Health Authority: United States: Food and Drug Administration
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)

Keywords provided by Cubist Pharmaceuticals Holdings LLC:
OBD (Induced Bowel Dysfunction)
cancer pain
pain medication
bowel dysfunction

Additional relevant MeSH terms:
Gastrointestinal Diseases
Intestinal Diseases
Digestive System Diseases
Signs and Symptoms
Signs and Symptoms, Digestive
Central Nervous System Agents
Gastrointestinal Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sensory System Agents
Therapeutic Uses processed this record on August 27, 2015